First Human Test of ER‑100 Aims to Reverse Age‑Related Sight Loss

A pioneering longevity startup has injected its experimental ER‑100 therapy into a human subject for the first time, inaugurating the inaugural clinical trial aimed at reversing age‑related vision loss. ER‑100 is presented as a cellular rejuvenation protocol that modifies epigenetic markers to reactivate pathways associated with youthful cell function. Pre‑clinical rodent studies show increased retinal thickness and improved visual acuity, suggesting the therapy may restore the regenerative capacity of the aging eye. Mechanistically, it appears to upregulate telomerase and dampen inflammatory senescence pathways, both implicated in age‑related vision decline. Set against rapid advances in CRISPR‑based therapies, senolytic drugs, and AI‑driven biomarker discovery, this trial exemplifies a broader industry shift toward treating aging as a modifiable physiological state rather than an inevitable decay, thereby opening avenues for preventive medicine across multiple organ systems. If the trial proves safe and effective, it could catalyze a new class of therapeutics that target the root causes of age‑related vision loss, reshaping pharmaceutical R&D incentives and prompting regulators to reconsider how longevity is measured and rewarded.